147 related articles for article (PubMed ID: 29500416)
1. Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.
Xu Y; Ikeda S; Sumida K; Yamamoto R; Tanaka H; Minato N
Nat Commun; 2018 Mar; 9(1):914. PubMed ID: 29500416
[TBL] [Abstract][Full Text] [Related]
2. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
3. Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
Supper E; Tahir S; Imai T; Inoue J; Minato N
PLoS One; 2015; 10(7):e0134026. PubMed ID: 26218064
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
5. Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Mukaida N; Tanabe Y; Baba T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829353
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
7. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells.
Schuh AC; Sutherland DR; Horsfall W; Mills GB; Dube I; Baker MA; Siminovitch K; Bailey D; Keating A
Leukemia; 1990 Sep; 4(9):631-6. PubMed ID: 2168506
[TBL] [Abstract][Full Text] [Related]
9. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
[TBL] [Abstract][Full Text] [Related]
10. [Chemokines in chronic myeloid leukemia].
Mukaida N; Baba T
Rinsho Ketsueki; 2016 Feb; 57(2):129-36. PubMed ID: 26935630
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R
J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174
[TBL] [Abstract][Full Text] [Related]
12. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
13. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.
Schürch C; Riether C; Matter MS; Tzankov A; Ochsenbein AF
J Clin Invest; 2012 Feb; 122(2):624-38. PubMed ID: 22232214
[TBL] [Abstract][Full Text] [Related]
14. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R
Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609
[TBL] [Abstract][Full Text] [Related]
15. IGF-IR determines the fates of BCR/ABL leukemia.
Xie J; Chen X; Zheng J; Li C; Stacy S; Holzenberger M; Hu X; Zhang CC
J Hematol Oncol; 2015 Feb; 8(1):3. PubMed ID: 25648584
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
Aggoune D; Sorel N; Bonnet ML; Goujon JM; Tarte K; Hérault O; Domenech J; Réa D; Legros L; Johnson-Ansa H; Rousselot P; Cayssials E; Guerci-Bresler A; Bennaceur-Griscelli A; Chomel JC; Turhan AG
Leuk Res; 2017 Sep; 60():94-102. PubMed ID: 28772207
[TBL] [Abstract][Full Text] [Related]
17. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
19. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
20. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
